ALK and non-small cell lung carcinoma: Camidge et al. reported the updated results of the phase I trial, carried out between August 2008 and June 2011, aiming to assess the tolerability and activity of crizotinib in 149 previously treated and untreated ALK-positive NSCLC patients.